Development of Complement Factor H-Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae.

Frontiers in Immunology
Jutamas ShaughnessySanjay Ram

Abstract

Novel therapeutics against the global threat of multidrug-resistant Neisseria gonorrhoeae are urgently needed. Gonococci possess several mechanisms to evade killing by human complement, including binding of factor H (FH), a key inhibitor of the alternative pathway. FH comprises 20 short consensus repeat (SCR) domains organized in a head-to-tail manner as a single chain. N. gonorrhoeae binds two regions in FH; domains 6 and 7 and domains 18 through 20. We designed a novel anti-infective immunotherapeutic molecule that fuses domains 18-20 of FH containing a D-to-G mutation in domain 19 at position 1119 (called FH*) with human IgG1 Fc. FH*/Fc retained binding to gonococci but did not lyse human erythrocytes. Expression of FH*/Fc in tobacco plants was undertaken as an alternative, economical production platform. FH*/Fc was expressed in high yields in tobacco plants (300-600 mg/kg biomass). The activities of plant- and CHO-cell produced FH*/Fc against gonococci were similar in vitro and in the mouse vaginal colonization model of gonorrhea. The addition of flexible linkers [e.g., (GGGGS)2 or (GGGGS)3] between FH* and Fc improved the bactericidal efficacy of FH*/Fc 2.7-fold. The linkers also improved PMN-mediated opsonophagocytosis ab...Continue Reading

References

Jul 1, 1991·Clinical Microbiology Reviews·J E Figueroa, P Densen
Nov 2, 1989·Nature·A HiattK Bowdish
Oct 1, 1987·Sexually Transmitted Diseases·R T EllisonF N Judson
Jan 15, 1988·The Biochemical Journal·J RipocheR B Sim
Feb 1, 1984·The Journal of Infectious Diseases·W M ShaferP F Sparling
Nov 4, 1994·Science·P E DawsonS B Kent
May 20, 2004·Bioconjugate Chemistry·Ian E GentleManuel Baca
Nov 7, 2007·Infection and Immunity·Lisa A LewisPeter A Rice
Oct 1, 1997·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·H D Keiser
Apr 25, 2009·PLoS Pathogens·Yogitha N SrikhantaMichael P Jennings
Oct 12, 2010·Clinical Microbiology Reviews·Sanjay RamPeter A Rice
Oct 20, 2010·Antimicrobial Agents and Chemotherapy·Keith L WycoffJohnny W Peterson
May 3, 2011·The Journal of Biological Chemistry·Jutamas ShaughnessyPeter A Rice
Jul 13, 2011·Frontiers in Microbiology·Ann E JerseLotisha E Garvin
Dec 30, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nirmal K BandaV Michael Holers
Sep 8, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Marije B OverdijkPaul W H I Parren
Oct 3, 2012·Advanced Drug Delivery Reviews·Xiaoying ChenWei-Chiang Shen
Apr 3, 2014·The Journal of Biological Chemistry·Michela SilacciDragan Grabulovski
Jul 1, 2014·BioMed Research International·Daniel TuséKaren A McDonald
Jul 2, 2014·Clinical Microbiology Reviews·Magnus Unemo, William M Shafer
Oct 11, 2014·Protein Engineering, Design & Selection : PEDS·Joshua S KleinPamela J Bjorkman
Feb 24, 2015·Journal of Biotechnology·Maximilian KlementDong-Yup Lee
Jul 23, 2015·PLoS Pathogens·David ErmertAnna M Blom
Aug 6, 2015·Plant Biotechnology Journal·Keith WycoffFrederick Hayden
Sep 1, 2015·The Journal of Antimicrobial Chemotherapy·Juan XueStijn van der Veen
Jan 17, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jutamas ShaughnessySanjay Ram

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
electrophoresis
protein Assay
flow cytometry

Software Mentioned

FlowJo
GENEWIZ

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.